Arch Therapeutics Inc (ARTH)

[Regis999]

Arch fully diluted shares is 168 million. Shares, warrants and options.

Closure Medical was a hemostasis company sold to JNJ. Thus the comparison in market cap versus sales price.




Buy Out Question


At $.675 market price Arch has a market cap of $113 million on a fully diluted basis of 168,061,159 shares.

So Closure Medical was sold to JNJ on 3/4/05 for $ 370 million. So we are only at 30% of that number.
Closure’s Dermabond is used in JNJ Liquid Band Air. Recall that some of the Closure’s Key People helped develop Arch’s AC-5.

I would argue that Arch’s 200 +/- applications are much deeper than the Closure apps. Most Arch's applications apply
to external uses such as Pressure Ulcers (bedsore), Foot Ulcers, Burns, etc. The external uses are the low hanging fruit
in which the current Europe human trials apply,

I believe that IF (BIG) Arch held out for a period of time they could approach $ 1 billion market cap but I am probably dreaming. In that case we would be 11% of the way there.

Summary of ARCH ARTH: http://www.archtherapeutics.blogspot.com/